GSK plc (GLAXF)

USD 16.84

(0.0%)

Long Term Debt Summary of GSK plc

  • GSK plc's latest annual long term debt in 2023 was 14.15 Billion GBP , down -16.91% from previous year.
  • GSK plc's latest quarterly long term debt in 2024 Q1 was 15.15 Billion GBP , up 7.08% from previous quarter.
  • GSK plc reported annual long term debt of 17.03 Billion GBP in 2022, down -17.19% from previous year.
  • GSK plc reported annual long term debt of 20.57 Billion GBP in 2021, down -12.18% from previous year.
  • GSK plc reported quarterly long term debt of 15.15 Billion GBP for 2024 Q1, up 7.08% from previous quarter.
  • GSK plc reported quarterly long term debt of 15.55 Billion GBP for 2023 Q2, down -6.55% from previous quarter.

Annual Long Term Debt Chart of GSK plc (2023 - 1989)

Historical Annual Long Term Debt of GSK plc (2023 - 1989)

Year Long Term Debt Long Term Debt Growth
2023 14.15 Billion GBP -16.91%
2022 17.03 Billion GBP -17.19%
2021 20.57 Billion GBP -12.18%
2020 23.42 Billion GBP -0.7%
2019 23.59 Billion GBP 16.37%
2018 20.27 Billion GBP 42.11%
2017 14.26 Billion GBP -2.71%
2016 14.66 Billion GBP -4.33%
2015 15.32 Billion GBP -3.26%
2014 15.84 Billion GBP 2.49%
2013 15.45 Billion GBP 5.35%
2012 14.67 Billion GBP 20.22%
2011 12.2 Billion GBP -17.6%
2010 14.8 Billion GBP 0.16%
2009 14.78 Billion GBP -2.92%
2008 15.23 Billion GBP 115.52%
2007 7.06 Billion GBP 48.09%
2006 4.77 Billion GBP -9.47%
2005 5.27 Billion GBP 20.31%
2004 4.38 Billion GBP 19.99%
2003 3.65 Billion GBP 18.08%
2002 3.09 Billion GBP 46.34%
2001 2.11 Billion GBP 20.67%
2000 1.75 Billion GBP 38.97%
1999 1.26 Billion GBP -30.16%
1998 1.8 Billion GBP -2.01%
1997 1.84 Billion GBP 8.36%
1996 1.69 Billion GBP 15.89%
1995 1.46 Billion GBP 438.97%
1994 272 Million GBP 28.3%
1993 212 Million GBP 54.74%
1992 137 Million GBP -2.14%
1991 140 Million GBP 218.18%
1990 44 Million GBP 37.5%
1989 32 Million GBP 166.67%

Peer Long Term Debt Comparison of GSK plc

Name Long Term Debt Long Term Debt Difference
AstraZeneca PLC 22.33 Billion USD 36.624%
Bristol-Myers Squibb Company PFD CONV 2 38.18 Billion USD 62.931%
CSPC Pharmaceutical Group Limited 107.05 Million USD -13120.871%
Clarus Therapeutics Holdings, Inc. - USD -Infinity%
Novartis AG 20.03 Billion USD 29.35%
PT Kalbe Farma Tbk. 19.39 Million USD -72889.253%